Obeticholic acid, a farnesoid X receptor (FXR) agonist structurally similar to chenodeoxycholic acid, has demonstrated positive effects in clinical trials for type 2 diabetes and NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.